The Search for Potent, Small‐Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat

@article{Zagni2017TheSF,
  title={The Search for Potent, Small‐Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat},
  author={Chiara Zagni and Giuseppe Floresta and G. Monciino and A. Rescifina},
  journal={Medicinal Research Reviews},
  year={2017},
  volume={37}
}
Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are involved in the epigenetic regulation of gene expression. In the last decade, inhibition of HDACs came out as a target for specific epigenetic changes associated with cancer and other diseases. Until now, more than 20 HDAC inhibitors (HDACIs) have entered clinical studies, and some of them (e.g., vorinostat, romidepsin) have been approved for the treatment of cutaneous T‐cell lymphoma. This review provides… Expand
47 Citations
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
  • PDF
Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC
  • PDF
Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)
  • 12
Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer
  • 1
Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
  • 10
Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent
  • 1
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 205 REFERENCES
Selective class IIa HDAC inhibitors: myth or reality
  • 27
Emerging approaches for histone deacetylase inhibitor drug discovery
  • 53
Design of novel histone deacetylase inhibitors.
  • 41
Inside HDACs with more selective HDAC inhibitors.
  • 118
Anticancer activities of histone deacetylase inhibitors
  • 2,544
  • PDF
...
1
2
3
4
5
...